封面： 标题：Peptide Half-Life Extension I: Fatty-Acid Acylation and Albumin BindingWhy lipidation became a clinically validated strategy for longer-acting peptide medicinesWhat does lipidation actually change?Fatty-acid acylation is often described as a simple conjugation step: attach a lipid chain to a
封面图：Beyond Half-Life: Six Routes to Longer-Acting Peptide Therapeutics Extending the half-life of a peptide is not always the same as extending its therapeutic value. The more relevant development goal is to create an exposure profile that supports the intended pharmacology, dosing interval, and the
Sichuan Pukang Pharmaceutical Phase II Facility Commissioned, Expanding Manufacturing Capacity for Long-Acting Peptide Raw Materials On May 15, 2026, the Phase II facility of Sichuan Pukang Pharmaceutical was officially completed and commissioned. Figure 1: Completion Ceremony for Phase II of Sichua
OLUMIANT is the first and only JAK inhibitor FDA-approved for the treatment of COVID-19 in certain hospitalized adults requiring various degrees of oxygen support.INDIANAPOLIS, May 11, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today the U.S. Food and
Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trialsWhile not indicated for weight loss, Mounjaro led to significantly greater weight reductions versus comparators in a key secondary endpointMounjaro represents the first new class of diabetes medicines
Diabodies are noncovalent dimers of single-chain antibody fragments that retain the avidity of intact IgG but have more favorable blood clearance than intact IgG. Radiometals offer a wide range of half-lives and emissions for matching imaging and therapy requirements and provide facile labeling of c
AbstractAn armed antibody (antibody-drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years. While in 2009 only gemtuzumab ozogamici
Newly published data show that participants maintained A1C and weight control up to two years in SURPASS-4, the largest and longest SURPASS trial completed to dateNo increased cardiovascular risk identified with tirzepatide; hazard ratio of 0.74 observed for MACE-4 events
RNA interference (RNAi) is a biological process in which RNA molecules are involved in sequence-specific suppression of gene expression by double-stranded RNA, through translational or transcriptional repression. Historically, RNAi was known by other names, including co-suppression, post-transcripti
Around 80% of disease-causing proteins, including key drivers of many cancers and other serious neurological conditions like Alzheimer’s disease, cannot be targeted by currently available therapeutics. These so called “undruggable” proteins lack specific surface areas required for treatments such as
Abstract: Semaglutide is a polypeptide compound with large molecularweight, hydrophilicity, and low permeability for the treatment of type 2 diabetes and obesity. Semaglutide injection has poor compliance that restricts its use, so semaglutide tablets appear. Semaglutide tablets mainly contain gluca
Source: Takashi Nakada, Kiyoshi Sugihara, Takahiro Jikoh, Yuki Abe, Toshinori Agatsuma ~The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy1. Introduction Traditional chemotherapy has been the predominant modality of
Another phase 3 clinical trial of Eli Lilly’s tirzepatide in Type 2 diabetics has met its primary endpoint. The dual GIP/GLP-1 agonist beat Novo Nordisk’s semaglutide against multiple measures, although recent data on another dose of the rival drug suggest Lilly has a fight on its hands.
Chengdu Pukang has a professional R&D team with rich experience, and innovative ideas, which can meet the various needs of customers from custom synthesis to mass production.
English
